Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Recurrence 1Mycosis Fungoides 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, B-Cell 1Hodgkin Disease 1

Interventions

Cyclophosphamide 12Biopsy 10Specimen Handling 9Whole-Body Irradiation 7Magnetic Resonance Spectroscopy 7pembrolizumab 6Peripheral Blood Stem Cell Transplantation 6Melphalan 6Etoposide 6fludarabine 5duvelisib 5Brentuximab Vedotin 5ruxolitinib 4fludarabine phosphate 4Vincristine 4Prednisone 4Doxorubicin 4Cytarabine 410-propargyl-10-deazaaminopterin 4romidepsin 3X-Rays 3Mycophenolic Acid 3Immunoglobulin G 3Granulocyte Colony-Stimulating Factor 3Gemcitabine 3Disulfides 3Carmustine 3venetoclax 2tazemetostat 2sodium-iodide symporter 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, T-Cell × AFM13 × 1 year × Clear all
NCT04074746 2025-09-30

Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas

M.D. Anderson Cancer Center

Phase 1/2 Completed
45 enrolled
Lymphoid

Mycosis Fungoides, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡